1. Olfactory dysfunction in β-thalassemia major patients treated with iron-chelating agents
- Author
-
Hatice Topal, Selvet Erdogan, Hatice Derin, Yaşar Topal, Murat Sahan, Mehmet Fatih Azik, Serhan Derin, MÜ, Eğitim ve Araştırma Hastanesi, Erdoğan, Selvet, and MÜ
- Subjects
Adult ,Male ,Beta-Thalassemia ,Blood transfusion ,Adolescent ,Pyridones ,medicine.medical_treatment ,Pharmacology ,Deferoxamine ,Iron Chelating Agents ,Benzoates ,Hemoglobins ,03 medical and health sciences ,Olfaction Disorders ,Young Adult ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,Blood Transfusion ,Deferiprone ,Chelation therapy ,030223 otorhinolaryngology ,Adverse effect ,business.industry ,beta-Thalassemia ,Age Factors ,Middle Aged ,Triazoles ,Chelation Therapy ,Deferasirox ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Ferritins ,Female ,business ,β thalassemia major ,030215 immunology - Abstract
WOS: 000490951400002 PubMed ID: 31142160 Ocular and ophthalmological adverse effects may be seen in beta-thalassemia major (BTM) patients treated with regular blood transfusions and iron-chelating agents. We hypothesized that olfactory dysfunction may be present in this population. In this study, we aimed to investigate olfactory dysfunction in patients with BTM and determine the etiological factors. A total of 43 patients with BTM were included in the study. Forty-three patients without any nasal complaints, history of facial trauma, or nasal surgery were included as the controls. All participants had nasal endoscopy. The iron-chelating agents used, their duration of use, as well as hemoglobin and ferritin levels of the BTM patients were recorded. Sniffin' Sticks test (SST) was used to assess olfactory functions, and BTM and control groups were compared for the results. The correlations of SST scores with the other study parameters were analyzed. Eight (18.6%) of 43 patients in the BTM group had hyposmia while none of the patients in the control group had hyposmia (P < .001). Older age, low-hemoglobin level, and longer use of deferoxamine were found to be correlated with olfactory dysfunction. Olfactory dysfunction may be seen in BTM patients treated with iron-chelating agents. The results of this study suggest that screening for olfactory function may be needed in routine follow-up of BTM patients. Mugla Sitki Kocman University, Department of Scientific Research ProjectsMugla Sitki Kocman University The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Mugla Sitki Kocman University, Department of Scientific Research Projects.
- Published
- 2017